/PRNewswire/ On Wednesday, May 26, 2021, Sofwave™ Medical made its initial public offering (IPO) on the Tel Aviv Stock Exchange (TASE). Sofwave s™, rapid.
Sofwave Medical Raises $50M and Completes Initial Public Offering on the Tel Aviv Stock Exchange
The Medical Aesthetic company which developed an innovative approach to wrinkle reduction raises $50 million in an initial public offering.
TUSTIN, Calif., June 3, 2021 /PRNewswire/ On Wednesday, May 26, 2021, Sofwave Medical made its initial public offering (IPO) on the Tel Aviv Stock Exchange (TASE). Sofwave s, rapid market adoption enabled the listing on the Tel Aviv Stock Exchange. The company managed to raise $50 million at a pre-money valuation of ~$200 million. The IPO was led by Barak Capital Underwriters.
Sofwave
TM is an emerging leader of energy-based non-invasive skin treatment aesthetic medical devices. The company is one of the only companies in the field of aesthetic medicine that is listed on TASE. The company has developed
JPost
May 31, 2021 7:15 PM ET
An Israeli biotechnology company has claimed a 100% success rate in the first 10 patients treated with its drug as part of an early-stage clinical trial at Rambam Health Care Campus in Haifa.
The company, Bonus BioGroup, presented the preliminary findings of its Phase I/II trial to peers at the International Society for Cell & Gene Therapy conference in New Orleans last week and shared the results in a statement released to the Tel Aviv Stock Exchange.
The Jerusalem Post, which first wrote about the treatment in May 2020, reviewed the PowerPoint presented at the conference and the five-page letter sent to the exchange. The company’s CEO and director, Dr. Shai Meretzki, told the Post that the team is now working on publishing its results in a peer-reviewed journal.